[Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against Locally Recurrent Bladder Cancer : A Case Report].

Abstract

A man in his 70s visited our hospital for gross hematuria. He was diagnosed with invasive urothelial carcinoma (cT3N2M0) and underwent total cystectomy and ileum conduit construction after three courses of neoadjuvant chemotherapy. Eight months after the operation, the disease reoccurred in the pelvic lesion. He received pembrolizumab therapy but developed idiopathic thrombocytopenic purpura (ITP) immediately before the ninth course of administration; and, treatment was discontinued. Recovery of symptoms and normalization of blood test data were achieved 3.5months after starting steroid treatment. Reduction of recurrent disease has been maintained for 2 years.

• Authors: Yuna Hattori, Manabu Kato, Tetsuya Imamura, Souta Inaba, Takashi Terabe, Momoko Kato, Shinichiro Higashi, Takeshi Sasaki, Satoru Masui, Yuko Yoshio, Kouhei Nishikawa, Katsunori Uchida, Takahiro Inoue
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 69 Issue 9 Pg. 255-258 (Sep 2023) ISSN: 0018-1994 [Print] Japan
• PMID: 37794676 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• pembrolizumab

Topics

• Humans
• Male
• Antibodies, Monoclonal, Humanized (adverse effects)
• Carcinoma, Transitional Cell
• Purpura, Thrombocytopenic, Idiopathic (chemically induced, drug therapy)
• Urinary Bladder Neoplasms (drug therapy, surgery, complications)
• Aged